Stockscreener 앱 받기
56.05
0.04%
0.02
시간 외 거래:
56.10
0.05
+0.09%
전일 마감가:
$56.03
열려 있는:
$56.48
하루 거래량:
1.44M
Relative Volume:
0.57
시가총액:
$10.37B
수익:
$2.69B
순이익/손실:
$-214.04M
주가수익비율:
-47.91
EPS:
-1.17
순현금흐름:
$98.43M
1주 성능:
+0.13%
1개월 성능:
-0.25%
6개월 성능:
+22.70%
1년 성능:
-14.30%
1일 변동 폭
$55.37
$57.23
1주일 범위
$54.45
$57.26
52주 변동 폭
$40.62
$79.62
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
EXAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
56.05 | 10.37B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
597.75 | 228.64B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
222.74 | 160.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
151.52 | 43.27B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
201.36 | 36.55B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
422.05 | 34.56B | 3.84B | 866.24M | 792.60M | 10.37 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Baader Bank Aktiengesellschaft Buys New Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Slow Capital Inc. Grows Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences to launch Oncodetect MRD test in Q2 2025 - MSN
Beacon Investment Advisory Services Inc. Sells 26,980 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Barclays Initiates Coverage of Exact Sciences (EXAS) with Overweight Recommendation - MSN
Assenagon Asset Management S.A. Buys 12,912 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Forecasting The Future: 19 Analyst Projections For Exact Sciences - Benzinga
Barclays sets Exact Sciences stock price target at $70 with Overweight rating - Investing.com
Exact Sciences Q4 EPS Estimate Reduced by Leerink Partnrs - MarketBeat
Exact Sciences (NASDAQ:EXAS) Now Covered by Analysts at Barclays - MarketBeat
Brokers Set Expectations for Exact Sciences FY2026 Earnings - MarketBeat
Leerink Partnrs Lifts Earnings Estimates for Exact Sciences - MarketBeat
Exact Sciences post positive results from MRD trial - Yahoo Finance
Exact Sciences to launch Oncodetect MRD test in Q2 2025 By Investing.com - Investing.com South Africa
Exact Sciences (EXAS): New Evidence Validates Oncodetect's Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients - StreetInsider.com
New Evidence Validates Oncodetect's Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients - Business Wire
Exact Sciences (NASDAQ:EXAS) Trading Up 5%Time to Buy? - MarketBeat
Exact Sciences showcases early cancer detection test data at AACR meeting - MSN
Avanza Fonder AB Acquires Shares of 19,512 Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
5,782 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Retirement Wealth Solutions LLC - MarketBeat
Brookstone Capital Management Decreases Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences (NASDAQ:EXAS) Stock Price Down 4.3%What's Next? - MarketBeat
Why Exact Sciences (EXAS) Is Crashing? - Insider Monkey
Exact Sciences Stock Drops 12% Over Four Days. 'What Is Going On?' - Yahoo! Voices
Beech Hill Advisors Inc. Sells 11,383 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
2 Healthcare Stocks to Buy Hand Over Fist in January - Yahoo Finance
Exact Sciences (NASDAQ:EXAS) Shares Gap UpStill a Buy? - MarketBeat
Exact Sciences (NASDAQ:EXAS) Trading Down 4.3%Here's Why - MarketBeat
William Blair Reaffirms "Outperform" Rating for Exact Sciences (NASDAQ:EXAS) - MarketBeat
Exact Sciences Stock Surges with Strong Financials - TipRanks
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market - Benzinga
Exact Sciences (NASDAQ:EXAS) Given Buy Rating at Benchmark - MarketBeat
Exact Sciences Boosts Finances and Plans New Launches - TipRanks
Exact Sciences expects Q4 and FY revenue to beat estimates - MSN
Exact Sciences Reports 10% Revenue Jump to $713M, Plans Three New Cancer Tests for 2025 - StockTitan
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat
Q2 EPS Estimate for Exact Sciences Increased by Analyst - MarketBeat
Should Exact Sciences Stock Stay in Your Portfolio Right Now? - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Exact Sciences Corporation Announces Appointment of Kim Popovits as A Class I Member of the Board - Marketscreener.com
Exact Sciences to participate in J.P. Morgan Healthcare Conferen - GuruFocus.com
Exact Sciences price target raised to $70 from $60 at Evercore ISI - Yahoo Finance
Exact Sciences to Participate in J.P. Morgan Healthcare Conference - Marketscreener.com
Exact Sciences to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Exact Sciences Announces Second-Quarter 2023 Results - GuruFocus.com
Exact Sciences Co. (NASDAQ:EXAS) Short Interest Down 5.3% in December - MarketBeat
(EXAS)Analyzing Exact Sciences's Short Interest - Benzinga
Exact Sciences Corporation's (NASDAQ:EXAS) Shift From Loss To Profit - Simply Wall St
Principal Financial Group Inc. Has $71.48 Million Stock Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Tidal Investments LLC Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
0.37%
자본화:
|
볼륨(24시간):